Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

sun pharma is buying organon & co in an all-cash deal valued at $11.75 billion, including debt. the indian drugmaker will pay $14 per share for the new jersey company, which was spun off from merck in 2021. organon specializes in women's health and biosimilars, with 70+ products sold across 140 countries. the acquisition pushes sun pharma, already india's largest drugmaker, into the top 25 global pharma companies with a combined revenue of $12.4 billion. sun pharma's innovative medicine segment — currently covering dermatology, ophthalmology, and onco-dermatology — will grow from 20% to 27% of total sales after the deal. organon shares had jumped nearly 31% on friday after an economic times report, citing sources, pegged the deal at about $13 billion. sun pharma closed 3.6% lower that day.